The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m2

MLA

Tatiana Dilla, et al. “The Cost-Effectiveness of Dulaglutide versus Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Spain in Patients with BMI ≥30 Kg/M2.” Journal of Medical Economics, vol. 20, Jan. 2017, pp. 443–52. EBSCOhost, https://doi.org/10.1080/13696998.2016.1275651.

APA

Tatiana Dilla, Ismini Chatzitheofilou, Ruba Ayyub, Dimitra Alexiou, Kirsi Norrbacka, & Julia Lowin. (2017). The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m2. Journal of Medical Economics, 20, 443–452. https://doi.org/10.1080/13696998.2016.1275651

Chicago

Tatiana Dilla, Ismini Chatzitheofilou, Ruba Ayyub, Dimitra Alexiou, Kirsi Norrbacka, and Julia Lowin. 2017. “The Cost-Effectiveness of Dulaglutide versus Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Spain in Patients with BMI ≥30 Kg/M2.” Journal of Medical Economics 20 (January): 443–52. doi:10.1080/13696998.2016.1275651.